IL176738A0 - Selective estrogen receptor modulators for the treatment of vasomotor symptoms - Google Patents

Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Info

Publication number
IL176738A0
IL176738A0 IL176738A IL17673806A IL176738A0 IL 176738 A0 IL176738 A0 IL 176738A0 IL 176738 A IL176738 A IL 176738A IL 17673806 A IL17673806 A IL 17673806A IL 176738 A0 IL176738 A0 IL 176738A0
Authority
IL
Israel
Prior art keywords
estrogen receptor
selective estrogen
treatment
vasomotor symptoms
receptor modulators
Prior art date
Application number
IL176738A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL176738A0 publication Critical patent/IL176738A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL176738A 2004-01-22 2006-07-06 Selective estrogen receptor modulators for the treatment of vasomotor symptoms IL176738A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53844204P 2004-01-22 2004-01-22
US53834204P 2004-01-22 2004-01-22
PCT/US2005/000020 WO2005073204A1 (en) 2004-01-22 2005-01-18 Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Publications (1)

Publication Number Publication Date
IL176738A0 true IL176738A0 (en) 2006-10-31

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176738A IL176738A0 (en) 2004-01-22 2006-07-06 Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Country Status (20)

Country Link
US (2) US20090023917A1 (https=)
EP (1) EP1709021B1 (https=)
JP (1) JP4909086B2 (https=)
KR (2) KR100849559B1 (https=)
CN (1) CN102250042A (https=)
AT (1) ATE476428T1 (https=)
AU (1) AU2005207821B2 (https=)
BR (1) BRPI0506721A (https=)
CA (1) CA2551956C (https=)
CR (1) CR8517A (https=)
DE (1) DE602005022673D1 (https=)
EA (2) EA012262B1 (https=)
EC (1) ECSP066711A (https=)
ES (1) ES2347973T3 (https=)
IL (1) IL176738A0 (https=)
MA (1) MA28436B1 (https=)
NO (1) NO20063760L (https=)
SG (1) SG149867A1 (https=)
UA (1) UA85862C2 (https=)
WO (1) WO2005073204A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
CA2738878C (en) * 2008-09-29 2013-08-13 Eli Lilly And Company Selective estrogen receptor modulator for the treatment of osteoarthritis
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形性形態
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
CN112424205B (zh) * 2018-07-12 2023-10-31 伊莱利利公司 选择性的雌激素受体降解剂
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CA3243621A1 (en) 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
CA2298651A1 (en) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
EA008024B1 (ru) * 2002-07-22 2007-02-27 Эли Лилли Энд Компани Селективные модуляторы эстрогенных рецепторов, содержащие фенилсульфонильную группу

Also Published As

Publication number Publication date
US20090023917A1 (en) 2009-01-22
KR101008804B1 (ko) 2011-01-14
CR8517A (es) 2006-12-01
EA012262B1 (ru) 2009-08-28
KR20060129277A (ko) 2006-12-15
KR100849559B1 (ko) 2008-07-31
US20110281847A1 (en) 2011-11-17
US8217032B2 (en) 2012-07-10
MA28436B1 (fr) 2007-02-01
BRPI0506721A (pt) 2007-05-02
CA2551956C (en) 2013-05-07
EA016613B1 (ru) 2012-06-29
ECSP066711A (es) 2006-10-31
SG149867A1 (en) 2009-02-27
AU2005207821A1 (en) 2005-08-11
EA200900586A1 (ru) 2009-08-28
AU2005207821B2 (en) 2011-02-10
CN102250042A (zh) 2011-11-23
KR20080016755A (ko) 2008-02-21
NO20063760L (no) 2006-10-16
CA2551956A1 (en) 2005-08-11
ATE476428T1 (de) 2010-08-15
WO2005073204A1 (en) 2005-08-11
DE602005022673D1 (de) 2010-09-16
UA85862C2 (uk) 2009-03-10
JP4909086B2 (ja) 2012-04-04
JP2007519721A (ja) 2007-07-19
ES2347973T3 (es) 2010-11-26
EP1709021B1 (en) 2010-08-04
EA200601353A1 (ru) 2007-02-27
EP1709021A1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
IL176738A0 (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
WO2008002490A3 (en) Treatment of vasomotor symptoms with selective estrogen receptor modulators
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
SI2150530T1 (sl) Substituirani sulfonamidni derivati
EA200900202A1 (ru) Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование
ZA200807986B (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
ZA200801732B (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MY142048A (en) Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
EP2010178A4 (en) SUBSTITUTED IMIDAZOLE-4-CARBOXAMIDES AS CHOLECYSTOKININ-1-RECEPTOR MODULATORS
MX2009004112A (es) Imidazoles sustituidos como moduladores del receptor de bombesina subtipo-3.
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.
WO2008113851A3 (en) Novel c11 modified retrosteroids as progesterone receptor modulator compounds
MY172530A (en) Method for treating gynecological diseases
DK2155674T3 (da) Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander
NO20080441L (no) Benzofuranonderivater som ikke-steroide progesteronreseptormodulatorer
WO2009071691A3 (de) Oxindol-derivate und ihre verwendung als medikament
WO2008128155A3 (en) SIRTUIN BASED METHODS AND COMPOSITIONS FOR TREATING β- CATENIN-RELATED CONDITIONS